Roche Media 23 févr. 2026 Roche halts development of Enspryng in Duchenne muscular dystrophy - Fierce Pharma
Roche Media 20 févr. 2026 Roche taps Aussie oncologist to lead research—Chutes & Ladders - Fierce Biotech
Roche Media 19 févr. 2026 Roche to end manufacturing of key antibiotic amid EU’s generic woes - Euractiv
Roche Media 9 févr. 2026 Roche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis - European Pharmaceutical Review
Roche Media 9 févr. 2026 Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech
Roche Media 6 févr. 2026 Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech
Roche Media 29 janv. 2026 Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News
Roche Media 29 janv. 2026 Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology
Roche Media 29 janv. 2026 Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review
Roche Media 29 janv. 2026 Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech
Roche Media 27 janv. 2026 Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
Roche Media 27 janv. 2026 How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine
Roche Media 27 janv. 2026 Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech
Roche Media 27 janv. 2026 Roche announces positive phase II results for experimental obesity drug - wkzo.com
Roche Media 26 janv. 2026 Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com